M.D. Anderson Cancer Center
The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved. Its use in this study is investigational.
Primary Objectives: To assess the association between imaging features on longitudinal HP 129Xe MRI and the development and severity of radiation pneumonitis resulting from radiation therapy for non-small cell lung cancer. To determine if HP 129Xe MRI features, in conjunction with a given patient's radiation treatment plan, can predict radiation pneumonitis development and severity. Secondary Objectives: Optimize HP 129Xe MRI acquisition techniques. To determine if HP 129Xe MRI can pre-emptively detect radiation pneumonitis prior to symptom presentation. Compare changes in HP 129Xe MRI m…
Inclusion Criteria: 1. Healthy control cohort: 1. Able to consistently hold breath for 10-12 seconds 2. No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.) 3. Able to undergo MRI examination 4. At least 18 years of age 2. Lung cancer patient cohort: 1. Biopsy proven diagnosis of lung cancer 2. Receiving photon- or proton-based external beam radiotherapy as a part of treatment 3. Able to undergo MRI examination 4. Will receive follow-up at University of Texas MD Anderson Cancer Center (UTMDACC) 5. Able to consistently hold breath for 10-12…
Gas delivery will be from a Tedlar bag
Arctuva estimate
Verify or correct the compensation shown for this listing.